The potential impact of P53 and APO-1 genetic polymorphisms on hepatitis C genotype 4a susceptibility

• Published in: Gene 2014-10, Vol.550 (1), p.40-45
• Main Authors: Eskander, Emad F., Abd-Rabou, Ahmed A., Mohamed, Mervat S., Yahya, Shaymaa M.M., El Sherbini, Ashraf, Shaker, Olfat G.
• Format: Article
• Language: English
• Subjects: Adult; APO-1 − 670A/G; fas Receptor - genetics; Female; Gene Frequency; Genetic Predisposition to Disease - genetics; Genotype; HCV genotype 4a; Hepacivirus - classification; Hepacivirus - genetics; Hepacivirus - physiology; Hepatitis C - genetics; Hepatitis C - virology; Host-Pathogen Interactions - genetics; Humans; Linkage Disequilibrium; Male; Middle Aged; P53 Arg72Pro; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral - genetics; SNPs; Tumor Suppressor Protein p53 - genetics
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2014.08.011

The hepatitis C virus (HCV), the main cause of morbidity and mortality, is endemic worldwide. HCV causes cirrhosis and other complications that often lead to death. HCV is most common in underdeveloped nations, with the highest prevalence rates in Egypt. Tumor suppressor gene (P53) induces the expression of apoptotic antigen-1 gene (APO-1) by binding to its promoter for mediating apoptosis; an important mechanism for limiting viral replication. This study aims at investigating the impact of P53 72 Arg/Pro and APO-1 −670 A/G polymorphisms on HCV genotype 4a susceptibility. Two hundred and forty volunteers were enrolled in this study and divided into two major groups; 160 HCV infected patient group and 80 healthy control group. HCV patients were classified according to Metavir scoring system into two subgroups; 72 patients in F0/1-HCV subgroup (patients with no or mild fibrotic stages) and 38 patients in F3/4-HCV subgroup (patients with advanced fibrotic stages). Quantification of HCV-RNA by qRT-PCR and fibrotic scores as well as genotyping of HCV-RNA, P53 at 72 Arg/Pro, and APO-1 at −670 A/G were performed for all subjects. It was resulted that F0/1-HCV patients have significant differences of P53 at 72 (Pro/Pro and Arg/Arg) genotypes and dominant/recessive genetic models as well as APO-1 −670 A/A genotype and dominant genetic model as compared to F3/4-HCV patients. Moreover, HCV patients have significant differences of P53 at 72 (Pro/Pro) genotype and recessive genetic model as well as APO-1 −670 A/A genotype and dominant genetic model as compared to those of healthy individuals. Finally, it was concluded that P53 rs 1042522 (Pro/Pro and Arg/Arg) genotypes and APO-1 rs 1800682 A/A genotype may be potentially used as sensitive genetic markers for HCV genotype 4a susceptibility. [Display omitted] •F3/4-HCV cases with the P53 72 homozygous genotypes had an impact on HCV severity.•F3/4-HCV cases with the APO-1 −670 A/A genotype loss had an impact on HCV severity.•HCV patients with the P53 72 Pro/Pro genotype had an increased risk of HCV infection.•HCV patients with the APO-1 −670 A/A genotype had a less risk of HCV infection.